American Association for Cancer Research Annual Meeting (AACR) | Conference

Matthew Krebs, MB, PhD, Reviews the Next Steps for Subcutaneous Amivantamab in Solid Tumors
May 09, 2022

Matthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.

Matthew Krebs, MB, PhD Discusses Phase 1 PALOMA Trial Results of Subcutaneous Amivantamab in Solid Tumors
April 29, 2022

Matthew Krebs, MB, PhD spoke about efficacy of subcutaneous amivantamab observed in the phase 1 PALOMA trial for patients with solid tumors.

Stéphane Champiat, MD, PhD, Talks Benefits With and Next Steps for SOT101 and Pembrolizumab
April 29, 2022

Stéphane Champiat, MD, PhD, spoke about the reasoning behind using the IL-2/IL-15 superagonist SOT101 and where the research is heading for patients with solid tumors.

Canakinumab Combination Doesn’t Lead to Survival Improvement But Could Benefit Subgroups With Advanced NSCLC
April 14, 2022

Although canakinumab, pembrolizumab, and chemotherapy did not lead to an improvement in survival vs the placebo cohort, it may still have benefit in certain subgroups of patients with previously untreated locally advanced or metastatic non–small cell lung cancer.

Neoadjuvant Durvalumab Plus Tremelimumab Combo Elicits Response in Advanced Ovarian Cancer
April 14, 2022

Data from the phase 2 KGOG 3046 trial revealed evidence of antitumor activity with the neoadjuvant chemoimmunotherapy regimen containing durvalumab and tremelimumab for patients with advanced-stage ovarian cancer.

Matthew Krebs, MB, PhD, Talks Rationale for the PALOMA Trial of Subcutaneous Amivantamab in Solid Tumors
April 13, 2022

Matthew Krebs, MB, PhD spoke about the reasoning for the phase 1 PALOMA trial in patients with solid tumors who received a subcutaneous formulation of amivantamab.

Clinical Activity Reported in Patients With Advanced Solid Tumors Treated With SOT101 Plus Pembrolizumab
April 13, 2022

Results of the phase 2 AURELIO-03 trial show SOT101 plus PD-1 inhibition induced responses in patients with advanced solid tumors.

Adebrelimab Plus Chemotherapy Meets OS End Point in SCLC
April 13, 2022

A phase 3 trial of patients with extensive-stage small cell lung cancer who were treated with adebrelimab plus chemotherapy compared with matched placebo met the primary end point of overall survival.

Oncolytic Adenovirus, CG0070, Plus Pembrolizumab Shows Promise in BCG-Unresponsive NMIBC
April 13, 2022

The addition of an immune checkpoint inhibitor to CG0070 induced a complete response rate of 88.9% among 18 patients in the phase 2 CORE1 trial.

Sotigalimab Plus Pembrolizumab Demonstrates Favorable Safety Profile in Metastatic Melanoma
April 13, 2022

The combination of sotigalimab plus pembrolizumab was associated with a tolerable safety profile in patients with unresectable stage III or IV metastatic melanoma.